Results: Baseline characteristics of the 173 pts with pJIA from the 6-17-year cohort were: median (min, max) age, 13.0 (6.0, 17.0) years; median (min, max) number of active joints, 10.0 (2.0, 42.0); 78.6% of pts used MTX (median dose: 11.6 mg/m 2 /week); and 26.6% were with prior biologic failure. All ADL limitation components improved from baseline to D113 (Month 4); these improvements were largely maintained at D309 (Figure) . Relative percentage D missed from school decreased from 15% (D1) to 5.5% (D309, Figure D) . CHAQ-DI and PaGA improved from baseline to D309 (Table) . Further 2-year data are pending.
Background:
In patients (pts) with polyarticular-course juvenile idiopathic arthritis (pJIA), SC abatacept (ABA) 125 mg weekly has a similar pharmacokinetic profile, therapeutically equivalent efficacy and comparable safety to IV ABA 10 mg/kg every 4 weeks. 1 Although some data on paediatric pt-reported outcomes (PRO) have been published for IV ABA, 2 PRO data following treatment with SC ABA have not. Results: Baseline characteristics of the 173 pts with pJIA from the 6-17-year cohort were: median (min, max) age, 13.0 (6.0, 17.0) years; median (min, max) number of active joints, 10.0 (2.0, 42.0); 78.6% of pts used MTX (median dose: 11.6 mg/m 2 /week); and 26.6% were with prior biologic failure. All ADL limitation components improved from baseline to D113 (Month 4); these improvements were largely maintained at D309 (Figure) . Relative percentage D missed from school decreased from 15% (D1) to 5.5% (D309, Figure D) . CHAQ-DI and PaGA improved from baseline to D309 (Table) . Further 2-year data are pending. 
Conclusions:
In this analysis of patients with pJIA aged 6-17 years, SC abatacept demonstrated a beneficial effect on PROs including reductions in activity limitation and disability (CHAQ-DI) and improvement in well-being (PaGA) up to D309.
